28-7 Therapeutics

28-7 Therapeutics is a biotechnology company specializing in the development of small molecule drugs that modulate RNA-binding proteins (RBPs). The company's core focus is the Lin28/let-7 pathway, a critical regulator of cell proliferation and differentiation that is often dysregulated in various cancers. By inhibiting the Lin28 protein, 28-7 aims to restore the levels of let-7 microRNA, which acts as a potent tumor suppressor. Their proprietary platform enables the discovery of small molecules that can specifically target RNA-protein interactions, opening new avenues for treating oncology and other high-need therapeutic areas. Founded by leading experts in RNA biology, the company is backed by a syndicate of top-tier life science investors.